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Introduction
The interest in Omega-3 polyunsaturated fatty acids and
coronary heart disease has arisen only over the course of the
past 25 years. In the 1970s, Danish investigators studied
heart disease rates in native peoples of Greenland and
discovered significantly lower levels of acute myocardial
infarction in Eskimos compared with age- and sex-matched
Danes. On further investigation, Bang and Dyerberg
concluded that the high level of Omega-3 fatty acids in their
native diet may have accounted for the low rates of coronary
heart disease (CHD). In studies of other populations such as
the Japanese, higher fish intake has also been associated
with lower rates of heart disease. In addition to replacing
meat (with its saturated fatty acids and cholesterol), fish
serves as the best source of long-chain ω3 fatty acids. By
the mid 1980￿s, Omega 3 fatty acids became the focus of
intense investigation.
Animal and clinical investigations into the functional
effects, health impact, and metabolism of Omega-3 fatty
acids have identified several promising uses of fish oil in
disease prevention and treatment. Although their greatest
impact may be in the arena of cardiovascular disease, a
beneficial role for this class of fatty acids has clearly been
implicated in several other systems. For example, it now
appears that Omega-3 fatty acids are essential nutrients
required in utero for proper development of nervous tissues.
The Omega-3 fatty acid most clearly needed is
docosahexaenoic acid (DHA; C22:6?3), the longest and
most unsaturated of all known dietary fatty acids.  It appears
that consumption of the plant-derived precursor of DHA, α-
linolenic acid (LNA; C18:??3), will provide enough DHA
for term infants. However, pre-term infants may need direct
delivery of DHA (and arachidonic acid; C20:??6) from the
placenta for proper brain development. There is currently
tremendous interest in fortifying infant formulas (especially
preterm) with DHA, although important unanswered
questions remain and are currently being addressed in
clinical trials.  Another area of  intense omega 3 research is
immunology. From rheumatoid arthritis, to psoriasis, IgA
nephropathy and colitis many research groups are exploring
the healing or preventive potential utility of this class of
natural products.  Another possible area in which the anti-
inflammatory effects of Omega-3 fatty acids may be playing
a major but still hidden role is in atherosclerosis. 
Heart Disease
It is in the arena of heart disease prevention that omega 3
fatty acids were first discovered. Although Omega-3 fatty
acids may play important roles in immune and inflammatory
responses, their impact on platelet function and lipoprotein
metabolism attracted most of the early attention. The
recognition that eicosapentaenoic acid (EPA), the other
major marine-derived Omega-3 fatty acid, was a substrate
for cyclooxygenase, and that thromboxane A3 was far less
biologically active than its arachidonic acid-derived
counterpart thromboxane A2, helped explain the prolonged
bleeding times in Greenland Eskimos. Subsequent research
revealed that the other 3-series icosanoids derived from
EPA (e.g., PGE3, leukotriene B5) also had reduced
physiological activity relative to their 2-series siblings. It
was these differences in metabolism between the EPA and
AA derived metabolites that were likely to be the basis for
not only the diminished thrombogenic vigor observed in
subjects taking fish oils, but  also for their anti-
inflammatory properties. Thus, part of the anti-atherogenic
mechanism of Omega-3 fatty acids is likely due to their
impact on eicosanoid metabolism. 
Lipoprotein metabolism was also affected by Omega-3 fatty
acids, but apparently not via alterations in eicosanoid
system. The effects of these fatty acids on serum
triglyceride reductions (both fasting and postprandial) has
been well-established. The mechanism of the triglyceride-
lowering effect involves an inhibition of hepatic triglyceride
synthesis and secretion with a possible effect on triglyceride
clearance still being investigated. Total cholesterol levels
usually do not change, whereas small increases in HDL-
cholesterol have frequently been reported. Like the
triglyceride-lowering fibrate drugs, LDL-cholesterol levels
can rise with ω3 fatty acid treatment, particularly in subjects
with significant hypertriglyceridemia; in other patients
changes are uncommon. Non-lipid effects on CHD risk
factors such as fibrinogen, blood viscosity or platelet
aggregation may also explain some of the beneficial effects
of fish oils on thrombosis and atherosclerosis. Finally,2
Omega-3 fatty acids may also play a role in the reduction of
blood pressure and thereby may reduce risk for CHD. 
Animal Studies
In one of the first well-controlled animal trials in this area,
Weiner et al. reported that pigs fed an atherogenic diet
supplemented with 30 ml/d of cod liver oil for 8 months
developed significantly less atherosclerosis than did the
control animals. Of particular interest was the lack of
association between LDL levels and atherosclerotic changes
in the arteries of pigs given fish oil; in fact, the LDL-
cholesterol concentrations were higher in the fish oil group.
Davis et al. studied the effects of feeding coconut oil with
two different doses of fish oil to Rhesus monkeys. In this
study, feeding higher levels of fish oil depressed HDL
levels. Nevertheless, there was a clear dose-response effect
between fish oil intake and less arterial plaque. These
observations suggest that Omega-3 fatty acids can improve
the atherogenic millieu even in the face of adverse changes
in serum lipids. Such adverse effects on serum lipoproteins
are not observed in humans consuming ￿practical￿ levels
(<4 g/d) of Omega-3 fatty acids.
Fish oil may play a role in preventing reperfusion injury to
the heart and brain.  In one study, rats were fed 12% of
calories either as corn oil or as fish oil for a month;
myocardial ischemia was induced by tying off the left main
coronary artery for 15 minutes and then reperfusing for 6
hours. Among the rats fed fish oil, 76% survived the ￿heart
attack￿ and 14% had ventricular tachycardia and fibrillation;
among those fed corn oil, the percentages were 41% and
90%, respectively.  Dog studies have shown that acute
infusion of EPA and DHA can reverse ventricular
fibrillation, strengthening the rationale for the use of these
acids in preventing rhythm disorders.  
Human Studies. There have been several epidemiological
studies comparing CHD rates between fish eating and non-
fish eating populations, and across the spectrum of fish
consumption within populations. Although these studies
have largely supported a cardioprotective effect of fish, the
link to Omega-3 fatty acids has been more difficult to
establish due to the low intake estimates characteristic of
diet survey studies. These uncertainties have been
addressed, however, in several prospective, randomized,
intervention trials using either oily fish, or more recently,
encapsulated fish oils or purified Omega-3 fatty acids. 
Intervention Studies. The first study to prospectively explore
the cardioprotective effect of Omega-3 fatty acids in a
secondary prevention population was the Diet and
Reinfarction Trial. Burr et al. studied 2,013 men who had
survived a heart attack.  Half were advised to eat oily fish
twice a week or to take fish oil capsules, while the other half
were advised only to eat a prudent diet. Survival over the
subsequent 2 years was followed. The researchers used food
diaries and blood EPA levels to confirm compliance. The
group advised to consume oily fish showed a 29% reduction
in overall, 2-year mortality compared with the control group.
Interestingly, there were no significant differences between
groups in total ischemic heart disease events because more
subjects in the fish oil group experienced nonfatal myocardial
infarctions while more subjects in the control group
experienced  fatal myocardial infarctions. These results
pointed to a possible protective effect for Omega-3 fatty acids
during ischemia and reperfusion.
Another prospective, randomized clinical trial using Omega-
3 fatty acids was reported by Singh et al.   Patients
presenting with suspected myocardial infarctions (n=360)
were randomized to placebo, fish oil (2 g of EPA+DHA per
day) or mustard seed oil (containing 2.9 g of α-linolenic
acid per day).  After one year, CHD events were
significantly reduced in both Omega-3 fatty acid groups.
Von Schacky and colleagues recently reported a small but
statistically significant reduction in angiographically-
determined CHD progression in a study which provided 6
g of Omega-3 fatty acids for 3 months followed by 3 g/d for
21 months or placebo in 223 patients. There were 7 CV
events in the control group and 2 in the Omega-3 group
(p=0.10). In a study of the effects of Omega-3 fatty acids on
coronary artery bypass graft patency, efficacy was highly
correlated to serum omega 3 fatty acid levels, with those
patients achieving the highest serum levels having an odds
ratio for graft occlusion of 0.49 compared to those with the
lowest increment in serum phospholipid Omega-3 fatty acid
levels. This finding illustrates the perhaps obvious fact that
differences in compliance and individual metabolism of
omega 3 fatty acids may contribute to differences in clinical
outcomes, and suggests that Omega-3 fatty acid levels in the
blood be assessed in all outcome studies.
The most recent test of the effects of omega 3 fatty acids on
CHD morbidity and mortality was the GISSI-Prevention
trial. This study was conducted in Italy and included 11,324
patients with known CHD. In a factorial design, … of the
patients were assigned to take vitamin E (300 mg/d);
another … were given 850 mg of omega 3 fatty acids daily
(one capsule of Omacor, Pronova Biocare, Oslo, Norway);
another … was given both and the final … received neither.
After 3.5 years of follow up, an intention-to-treat analysis
revealed that total mortality in the patients given omega 3
fatty acids was 21% lower than in those patients not so
treated, and the incidence of sudden cardiac death was
reduced by 45%. Vitamin E showed a beneficial trend but
it was not statistically significant. These results were
achieved despite the fact that over 25% of patients reported
that they stopped taking the capsules. The finding of the3
GISSI-Prevention study provide strong support for the use
of Omega-3 fatty acids in secondary prevention of acute
coronary syndromes. The mechanisms by which Omega-3
fatty acids protect against cardiac death are not known with
certainty, but may relate to their ability to prevent cellular
damage during periods of ischemic stress.  
In conclusion, the evidence for a protective role of omega
3 fatty acids in CHD is becoming clearer and firmer,
especially for secondary prevention. Intakes of
approximately 800-1,000 mg per day appear to be a prudent
approach for the latter group of patients. The safety of
intakes of up to 3,000 mg per day has been endorsed by the
recent ruling of the FDA that this level of EPA+DHA (from
menhaden oil) is generally recognized as safe (GRAS) for
inclusion in the American food supply. Recommendations
for primary prevention of CHD and for use in other
conditions (inflammatory diseases, autoimmune conditions,
cancer prevention, etc.) cannot yet be made as the requisite
data to support such recommendations is not yet available.
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